Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C38H59FO6 |
Molecular Weight | 630.8699 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=WDPYZTKOEFDTCU-WDJQFAPHSA-N
InChI=1S/C38H59FO6/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-34(43)45-26-33(42)38(44)27(2)23-31-30-20-19-28-24-29(40)21-22-35(28,3)37(30,39)32(41)25-36(31,38)4/h21-22,24,27,30-32,41,44H,5-20,23,25-26H2,1-4H3/t27-,30+,31+,32+,35+,36+,37+,38+/m1/s1
Molecular Formula | C38H59FO6 |
Molecular Weight | 630.8699 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ndrugs.com/?s=limethason
Curator's Comment: Description was created based on several sources, including http://www.ndrugs.com/?s=limethason
Dexamethasone palmitate (a derivative of Dexamethasone), anti-inflammatory, antirheumatic, glucocorticoid receptor agonist, is reported as an ingredient of Limethason in Japan and Lipotalon in Germany. Limethason (Dexamethasone palmitate) inhibits the function of leukocytes and tissue macrophages. It restricts the migration of leukocytes in the area of inflammation. Limethason (Dexamethasone palmitate) decreases capillary permeability caused by histamine release. It inhibits the activity of fibroblasts and collagen formation. Limethason inhibits the activity of phospholipase A2, which leads to suppression of the synthesis of prostaglandins and leukotrienes. Limethason (Dexamethasone palmitate) is indicated for rheumatoid arthritis.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Macrophage viability and migration Sources: https://www.ncbi.nlm.nih.gov/pubmed/24806147 |
|||
Target ID: CHEMBL2034 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D01615 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Limethason Approved UseIndications: rheumatoid arthritis Launch Date1988 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17275235
0.25mg/kg, intravenous
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24806147
DEXAMETHASONE PALMITATE decreased the viability of RAW 264.7 cells by 75% at a concentration of 10 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:03:15 GMT 2023
by
admin
on
Sat Dec 16 02:03:15 GMT 2023
|
Record UNII |
601XWN7060
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
828
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
C035081
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL384467
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
601XWN7060
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
SUB01611MIG
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
14899-36-6
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
63044
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
DTXSID8022903
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY | |||
|
100000092376
Created by
admin on Sat Dec 16 02:03:15 GMT 2023 , Edited by admin on Sat Dec 16 02:03:15 GMT 2023
|
PRIMARY |